Feb 10, 2022 / 01:30PM GMT
Operator
Greetings, and welcome to the SCYNEXIS Inc. Corporate Update Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn this conference over to your host, Ms. Debbie Etchison, Investor Relations. Thank you, ma'am. You may begin.
Debbie Etchison - SCYNEXIS, Inc. - Executive Director of Communications
Hello, everyone, and welcome to today's conference call to discuss results from our CANDLE trial in recurrent vulvovaginal candidiasis, or RVVC.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership's expectations for our clinical results, future financial and operational performance as well as our business strategy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Please refer to our filings in the Securities and Exchange Commission,
SCYNEXIS Inc Corporate Update Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot